Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

NCT02447380 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
2
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Samsung Medical Center